Promising combo tackles rare blood cancer in early study
NCT ID NCT07233720
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a two-drug combination (zanubrutinib and rituximab) as a first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo to see how well it shrinks tumors and delays the cancer from getting worse. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
RECRUITINGZhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients
- New drug combo aims to tackle Hard-to-Treat lymphoma